Skip to content

Released Aug 9, 2021, before the open

10-Q filed Aug 9, 2021, 40 days after period end · 0001764013-21-000079

Q1 2022 · 10-Q
Revenue—
Net Income-$30.47Mno prior Q1 2021 on fileN/M vs Q1 2019
EPS Diluted-$0.31no prior Q1 2021 on fileN/M vs Q1 2019
Operating Cash Flow-$21,214,000—
Free Cash Flowderived-$21,232,000—

What the release said

The release

Same quarter

MetricQ1 2022Q1 2019Q1 2018
Net Income-$30.47M-$20.06M-$4.37M
EPS Diluted-$0.31-$0.52—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR